Richard Pfenniger, Jr. has served on has served on the Board of Directors at GeneDx (formerly Sema4) since May 2022.
Richard is an experienced executive with significant expertise in the life science, healthcare, and education fields.
During his career, Richard has been an executive officer at several companies, including CEO and President of Continucare Corporation, a provider of primary care physician and practice management services, where he also served as Chairman of the Board of Directors. Previously, he was the CEO and Vice Chairman of Whitman Education Group, Inc. Prior to joining Whitman, he served in several different roles at IVAX Corporation, including COO, Senior Vice President- Legal Affairs, and General Counsel. Before that, Richard was engaged in the private practice of law.
In addition to GeneDx, Richard currently serves as a member of the Board of Directors for Opko, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, Asensus Surgical, Inc. (NYSE: ASXC), a medical device company, and Cocrystal Pharmaceuticals, Inc. (NASDAQ: COCP), a clinical stage biotechnology company. He is also the Vice Chairman of the Board of Trustees and a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science.
Richard previously served as a director of GP Strategies Corporation (NYSE: GPX), a corporate education and training company, BioCardia, Inc. (NASDAQ: BCDA), a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases, and Wright Investors’ Services Holdings, Inc. (OTC US: IWSH), an investment management and financial advisory firm.
Richard received a Juris Doctor degree from the University of Florida and a Bachelor of Business Administration degree from Florida Atlantic University.
What is Richard C. Pfenniger, Jr.'s net worth?
The estimated net worth of Richard C. Pfenniger, Jr. is at least $29.97 million as of January 5th, 2024. Mr. Pfenniger, Jr. owns 325,000 shares of GeneDx stock worth more than $29,965,000 as of March 29th. This net worth estimate does not reflect any other investments that Mr. Pfenniger, Jr. may own. Learn More about Richard C. Pfenniger, Jr.'s net worth.
How do I contact Richard C. Pfenniger, Jr.?
Has Richard C. Pfenniger, Jr. been buying or selling shares of GeneDx?
Richard C. Pfenniger, Jr. has not been actively trading shares of GeneDx within the last three months. Most recently, on Wednesday, November 8th, Richard C. Pfenniger, Jr. bought 10,000 shares of GeneDx stock. The stock was acquired at an average cost of $1.49 per share, with a total value of $14,900.00. Following the completion of the transaction, the director now directly owns 20,918 shares of the company's stock, valued at $31,167.82. Learn More on Richard C. Pfenniger, Jr.'s trading history.
Who are GeneDx's active insiders?
GeneDx's insider roster includes Shawn Assad (CAO), Daniel Clark (General Counsel), James Coffin (COO), Kevin Feeley (CFO), Richard Pfenniger, Jr. (Director), Richard Pfenniger, Jr. (Director), Anthony Prentice (Insider), Isaac Ro (CFO), Jason Ryan (Chairman of the Board), Eric Schadt (CEO), and Katherine Stueland (CEO). Learn More on GeneDx's active insiders.
Are insiders buying or selling shares of GeneDx?
In the last year, GeneDx insiders bought shares 4 times. They purchased a total of 175,804 shares worth more than $3,771,670.44. In the last year, insiders at the sold shares 54 times. They sold a total of 2,071,808 shares worth more than $124,885,397.13. The most recent insider tranaction occured on March, 26th when CFO Kevin Feeley sold 8,746 shares worth more than $836,205.06. Insiders at GeneDx own 27.3% of the company.
Learn More about insider trades at GeneDx. Information on this page was last updated on 3/26/2025.
